Renaissance Technologies’s Acrivon Therapeutics ACRV Stock Holding History

Renaissance Technologies’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Buy	758,863 +423	+0.1%	+$719	﹤0.01%	2170
2026 Q1	$1.05M	Buy	758,440 +124,271	+20%	+$217K	﹤0.01%	2245
2025 Q4	$1.53M	Buy	634,169 +10,769	+2%	+$23.4K	﹤0.01%	2037
2025 Q3	$1.13M	Buy	623,400 +114,105	+22%	+$160K	﹤0.01%	2419
2025 Q2	$606K	Buy	509,295 +457,195	+878%	+$627K	﹤0.01%	2743
2025 Q1	$106K	Buy	52,100 +2,700	+5%	+$14.5K	﹤0.01%	3189
2024 Q4	$297K	Buy	49,400 +3,500	+8%	+$25.4K	﹤0.01%	3045
2024 Q3	$321K	Sell	45,900 -8,600	-16%	-$67.8K	﹤0.01%	2959
2024 Q2	$316K	Sell	54,500 -48,100	-47%	-$387K	﹤0.01%	2889
2024 Q1	$734K	Buy	+102,600	New	+$476K	﹤0.01%	2675

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies's ACRV Position: Q2 2026 in Review

Renaissance Technologies increased its Acrivon Therapeutics (ACRV) stake by 0.06% in Q2 2026, buying an estimated $719 and bringing the position to 758,863 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2170.

Renaissance Technologies first reported a position in ACRV in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.53M in Q4 2025. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

Renaissance Technologies held 758,863 shares of Acrivon Therapeutics worth $1.35M as of Q2 2026.
Renaissance Technologies bought 423 Acrivon Therapeutics shares in Q2 2026, an estimated $719.
Acrivon Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2170 holding.
Renaissance Technologies first reported a position in Acrivon Therapeutics in Q1 2024 and has held it in 10 quarters since.
Renaissance Technologies's Acrivon Therapeutics position peaked at $1.53M in Q4 2025.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.